for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Genscript Biotech Corp

1548.HK

Latest Trade

17.00HKD

Change

0.60(+3.66%)

Volume

7,984,284

Today's Range

16.24

 - 

17.00

52 Week Range

9.43

 - 

24.45

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
16.40
Open
16.24
Volume
7,984,284
3M AVG Volume
97.23
Today's High
17.00
Today's Low
16.24
52 Week High
24.45
52 Week Low
9.43
Shares Out (MIL)
1,862.12
Market Cap (MIL)
30,203.57
Forward P/E
312.98
Dividend (Yield %)
--

Next Event

Genscript Biotech Corp Annual Shareholders Meeting

Latest Developments

More

Genscript Biotech HY Loss Attributable Us$27.3 Million

Genscript Biotech Expects HY Loss Of About US$29.4 Mln To US$44.2 Mln

Genscript Biotech Corp Updates On Development Of LCAR-B38M (JNJ-4528) In Multiple Myeloma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Genscript Biotech Corp

Genscript Biotech Corporation is a Hong Kong-based investment holding company principally engaged in life science research and related businesses. The Company operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.

Industry

Biotechnology & Drugs

Contact Info

No. 28

Yongxi Road, Jiangning Science Park

+86.25.58897288

https://www.genscript.com

Executive Leadership

Fangliang Zhang

Executive Chairman of the Board, Chief Executive Officer

Ye Wang

President, Co-Founder, Executive Director

Jiange Meng

Vice President - Investor Relations, Executive Director

Li Zhu

Vice President - Strategy

Zhiqiang Chen

Senior vice President - Public Relation Department

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.2K

2018

0.2K

2019(E)

0.3K
EPS (USD)

2016

0.015

2017

0.015

2018

0.012

2019(E)

0.007
Price To Earnings (TTM)
--
Price To Sales (TTM)
16.00
Price To Book (MRQ)
8.47
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.44
LT Debt To Equity (MRQ)
1.35
Return on Investment (TTM)
-4.12
Return on Equity (TTM)
-3.40

Latest News

Latest News

Amgen antibody shows promise in myeloma trial, gets FDA fast track

Amgen Inc <AMGN.O>, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.

Hong Kong market could open cash flood gates for U.S. biotechs

When U.S. biotech startup Sorrento Therapeutics named ex-Lehman Brothers executive Jiong Shao as its new finance chief about two months ago, it was widely seen as a move driven by his background in raising capital for Alibaba and Tencent.

BRIEF-Genscript Biotech Announces Unit ‍Received Permission Of Clinical Trial Granted By China FDA

* UNIT RECEIVED PERMISSION OF CLINICAL TRIAL GRANTED BY CHINA FDA WITH RESPECT TO LCAR- B38M CAR-T FOR AUTOLOGOUS INFUSION Source text for Eikon: Further company coverage:

BRIEF-Genscript Biotech Says ‍Huang Zuie-Chin Resigns As Non-Executive Director​

* HUANG ZUIE-CHIN RESIGNED AS A NON-EXECUTIVE DIRECTOR Source text for Eikon: Further company coverage:

BRIEF-Genscript Biotech Announces Acquisition Of Customarray

* ANNOUNCES ACQUISITION OF 100% OF ENTIRE ISSUED SHARES OF CUSTOMARRAY, INC. Source text for Eikon: Further company coverage:

BRIEF-Genscript Biotech Says US, Ireland Units ‍& Janssen Biotech Enter Collaboration & License Agreement ​

* US, IRELAND UNITS & JANSSEN BIOTECH ENTER COLLABORATION & LICENSE AGREEMENT TO DEVELOP MULTIPLE MYELOMA PRODUCTS

BRIEF-Janssen Enters Collaboration And License Agreement With China's Legend Biotech To Develop CAR-T Cancer Therapy

* JANSSEN ENTERS WORLDWIDE COLLABORATION AND LICENSE AGREEMENT WITH CHINESE COMPANY LEGEND BIOTECH TO DEVELOP INVESTIGATIONAL CAR-T ANTI-CANCER THERAPY

BRIEF-Genscript Biotech Unit's‍ Application For Investigational New Drug Accepted By China FDA

* APPLICATION FOR INVESTIGATIONAL NEW DRUG BY UNIT ACCEPTED BY CHINA FDA Source text for Eikon: Further company coverage:

BRIEF-Genscript Biotech Corp updates on shareholding changes in GS Corp ​

* INFORMED THAT ADDITIONAL 50 MILLION SHARES & 25 MILLION SHARES OF GS CORP WERE TRANSFERRED TO ZHANG TRUST & WANG TRUST, RESPECTIVELY Source text for Eikon: Further company coverage:

BRIEF-Genscript Biotech Corp says ‍Kanglitai informed by CFDA of approval on clinical trial

* Kanglitai informed by CFDA of approval on clinical trial; approved to commence clinical studies of KLT-1101 Source text for Eikon: Further company coverage:

BRIEF-Genscript Biotech Corp updates on transfer of shares of GS Corp

* Informed by GS Corp that 5 million shares & 2.5 million shares of GS Corp were transffered to Zhang Trust and Wang Trust respectively Source text for Eikon: Further company coverage:

BRIEF-Genscript Biotech Corp says HY revenue of group about US$63.4 million

* HY profit attributable to shareholders of company up 13.6% to about US$15.0 million Source text for Eikon: Further company coverage:

BRIEF-Genscript Biotech Corp says Bsj Nanjing enters BSJ capital increase agreement with Prc Fund

* Bsj Nanjing entered into bsj capital increase agreement with prc fund and bsj hk

Blood and bone marrow therapies grab spotlight at world's top cancer meeting

Promising new data on blood and bone marrow cancer therapies that re-engineer immune system cells are convincing more doctors of the validity of the approach, according to Reuters interviews at the world's biggest annual oncology meeting.

Chinese cell therapy effective in small multiple myeloma trial

A small trial conducted in China found that an experimental therapy using altered cells to recruit the body's immune system to attack cancer can induce remission in most patients with advanced multiple myeloma, a blood plasma cancer.

BRIEF-Genscript Biotech updates on development of new drug​

* application for clinical trial on KLT-1101 was accepted by China food and drug administration on 4 May 2017. Source text for Eikon: Further company coverage:

BRIEF-Genscript Biotech Corp enters into a termination agreement

* Company and china resources parties have entered into a termination agreement

BRIEF-Genscript Biotech expected to record a significant increase in net profit for year ended Dec. 31, 2016

* Group is expected to record a significant increase in net profit for year ended December 31, 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up